[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Besse B, Grunenwald D, Fléchon A, Caty A, Chevreau C, Culine S, Théodore C, Fizazi K: Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg; 2009 Feb;137(2):448-52
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Our objective was to explore the pathologic components of residual masses after primary chemotherapy in patients with metastatic nonseminomatous germ cell tumors.
  • METHODS: A multicenter retrospective study was conducted of 71 patients with thoracic residual masses (39 patients had bilateral lung metastasis) after first-line cisplatin-based chemotherapy for disseminated nonseminomatous germ cell tumors.
  • RESULTS: Pathologic findings in postchemotherapy residual masses included complete necrosis, teratoma, and viable cancer in 31%, 55%, and 14% of patients, respectively.
  • A single patient had necrosis only in the first lung and some teratoma in the contralateral lung.
  • Avoiding contralateral lung surgery could therefore be considered when complete necrosis is found in the first lung after induction chemotherapy for nonseminomatous germ cell tumor.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / drug therapy. Pneumonectomy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Choriocarcinoma / drug therapy. Choriocarcinoma / pathology. Cisplatin / therapeutic use. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / pathology. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinal Neoplasms / secondary. Necrosis. Retroperitoneal Neoplasms / secondary. Retrospective Studies. Teratoma / drug therapy. Teratoma / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185168.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Sanchez D, Zudaire JJ, Fernandez JM, Lopez J, Arocena J, Sanz G, Gimenez M, Rosell D, Robles JE, Berian JM: 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int; 2002 Jun;89(9):912-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse.
  • OBJECTIVES: To compare the performance of 18F-fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) in the follow-up of nonseminomatous germ cell tumours (NSGCT) in the retroperitoneum.
  • PATIENTS AND METHODS: FDG-PET was used 25 times in 15 patients diagnosed with NSGCT.
  • At the time of diagnosis five patients each were in stage I, II and III.
  • Five patients had pure embryonal carcinoma, two had yolk sac tumours, one choriocarcinoma and seven had mixed tumours.
  • RESULTS: Eleven patients either presented with retroperitoneal disease or this did not disappear after chemotherapy.
  • CONCLUSION: In these patients FDG-PET detected the retroperitoneal relapse of NSGCT, in advanced stages treated with surgery plus chemotherapy, earlier than did CT; it also detected the presence of mature teratoma in residual retroperitoneal masses more accurately than CT.
  • [MeSH-major] Fluorodeoxyglucose F18. Germinoma / radionuclide imaging. Radiopharmaceuticals. Retroperitoneal Neoplasms / radionuclide imaging. Testicular Neoplasms / radionuclide imaging. Tomography, Emission-Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12010239.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Matveev VB, Volkova MI, Cherniev VA, Figurin KM, Mitin AV: [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers]. Urologiia; 2010 May-Jun;(3):41-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers].
  • Postchemotherapy retroperitoneal lymph node dissection (RLND) was performed in 70 testicular non-seminoma patients with elevated serum tumor markers (age median 27.0 +/- 8.1 years) from 1983 to 2008.
  • The prognostic group was not identified in 24 (34.3%) cases which started treatment in other hospitals.
  • All the patients received induction cisplatin-based chemotherapy following orchidectomy (first-line--24 (34.3%), second-line--46 (65.7%) which resulted in tumor shrinkage < 50% in 7 (10.0%), 51-90% in 23 (32.9%), > 90%--in 2 (2.9%) cases.
  • CT scan revealed residual retroperitoneal masses after chemotherapy in all the patients: < 2 cm--5 (7.1%), 2-5 cm--25 (35.7%), > 5 cm--40 (57.1%).
  • Further chemotherapy was not perspective in all 70 patients who further underwent retroperitoneal lymph node dissection (RLND).
  • Postoperative chemotherapy was given to 27 (38.6%) cases.
  • Complications developed in 12.9% (9/70) patients.
  • Histology revealed necrosis in 20 (28.6%), teratoma--in 26 (37.1%), cancer--in 24 (34.3%) specimens.
  • Prognostic factors for cancer in retroperitoneal pathology were the following: S > S1 (p = 0.013), intermediate or poor prognosis group IGCCCG (p = 0.014), absence of embryonal carcinoma (p = 0.003), the presence of choriocarcinoma in the testicular tumor (p = 0.028), second-line chemotherapy (p = 0.001), residual mass > 2 cm (p = 0.006).
  • Univariate analysis revealed an adverse impact on progressive-free survival of category S > S1 (p = 0.015), intermediate or poor prognostic group IGCCCG (p = 0.01), the presence of embryonal carcinoma (p = 0.020) and the absence of choriocarcinoma in the testicular tumor (p = 0.029), tumor shrinkage < 50% (p < 0.0001), incomplete RLND (p = 0.012), an incomplete effect of the combined treatment (p < 0.0001), cancer in the residual mass (p < 0.0001).
  • The multivariate analysis proved predictive value of an incomplete effect of the combined treatment (p < 0.0001).
  • Thus, selected testicular non-seminoma patients with elevated serum tumor markers are curable with surgery.
  • The best candidates for RLND in this group are patients without a tumor markers level increase during chemotherapy, with S1 category, good IGCCCG prognosis, tumor shrinkage > 50% and potentially respectable residual disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Germinoma. Lymph Node Excision. Testicular Neoplasms

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734877.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Michael H, Lucia J, Foster RS, Ulbright TM: The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol; 2000 Feb;24(2):257-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathology of late recurrence of testicular germ cell tumors.
  • A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a subsequent disease-free interval of at least 2 years and no evidence of a second primary lesion.
  • Ninety percent of the patients for whom information was available received chemotherapy shortly after their initial diagnosis of testicular germ cell tumors; most of the other patients were known to have stage I disease initially.
  • Overall, 60% of patients had teratoma in their late recurrences, including 20 patients (22%) in whom teratoma was the only element.
  • Thus, teratoma was the most common type of neoplasm in late recurrences.
  • Excluding teratoma coexisting with other types of neoplasms, yolk sac tumor was the most frequent type of tumor in patients with late recurrence.
  • It occurred in 47% of patients, either alone or with teratoma, another nonteratomatous germ cell tumor type, or a "nongerm cell malignant tumor."
  • Unusual types of yolk sac tumor, including glandular, parietal, clear cell, and pleomorphic patterns, were seen frequently in late recurrences and often raised differential diagnostic problems with "nongerm cell" carcinomas.
  • A smaller number of late recurrences consisted of other types of neoplasms.
  • Most of these nonteratomatous germ cell tumors other than yolk sac tumor were embryonal carcinoma, although rarely seminoma and choriocarcinoma were encountered.
  • "Nongerm cell malignant tumors," including both sarcomas and carcinomas of various types, occurred in 23% of late-recurrence patients, either alone or with a nonteratomatous germ cell tumor.
  • Patients whose late recurrences consisted of teratoma only had the most favorable outcomes, with 79% having no evidence of disease at last follow-up.
  • Patients whose late recurrences consisted of pure "nongerm cell malignant tumor" or pure germ cell tumor (yolk sac tumor or other types) had a much worse prognosis: Only 36% to 37% were alive with no evidence of disease.
  • Patients with two different types of nonteratomatous malignancies in their late recurrences had a dismal clinical course: Only 17% with both yolk sac tumor and other nonteratomatous germ cell tumor had no evidence of disease, whereas no patient with both nonteratomatous germ cell tumor and "nongerm cell malignant tumor" was disease free.
  • Late recurrences consisting of teratoma alone often have a favorable outcome, but the prognosis in all other patients is poor.
  • Furthermore, late recurrence is not likely to respond to chemotherapy and is best treated by surgical excision when possible.
  • [MeSH-major] Germinoma / pathology. Neoplasm Recurrence, Local / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Choriocarcinoma / complications. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Fluorescent Antibody Technique, Direct. Humans. Male. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Sarcoma / complications. Sarcoma / pathology. Sarcoma / therapy. Seminoma / complications. Seminoma / pathology. Seminoma / therapy. Teratoma / complications. Teratoma / pathology. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10680894.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


5. Eid H, Mingfang L, Institoris E, Bodrogi I, Bak M: MRP expression of testicular cancers and its clinical relevance. Anticancer Res; 2000 Sep-Oct;20(5C):4019-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRP expression of testicular cancers and its clinical relevance.
  • However, there is a lack of data regarding its expression in germ cell testicular tumors (GCTTs).
  • PATIENTS AND METHODS: MRP expression was examined by immunohistochemistry (IHC) using mouse monoclonal antibody (MRPm6) against human MRP in 56 testis cancer specimens.
  • RESULTS: All testis tumors, regardless of their histology, metastatic status and clinical stage gave positive signals.
  • Since germ cell tumors are very sensitive to chemotherapy, the role of MRP as mediator of drug resistance seems unconvincing in this malignancy.
  • [MeSH-major] ATP-Binding Cassette Transporters / analysis. Drug Resistance, Multiple. Testicular Neoplasms / pathology
  • [MeSH-minor] Animals. Antibodies, Monoclonal. Choriocarcinoma / pathology. Choriocarcinoma / surgery. Humans. Immunohistochemistry. Male. Mice. Multidrug Resistance-Associated Proteins. Neoplasm Proteins / analysis. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / surgery. Seminoma / pathology. Seminoma / surgery. Teratoma / pathology. Teratoma / surgery. Testis / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268495.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / Antibodies, Monoclonal; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


6. Dimov ND, Zynger DL, Luan C, Kozlowski JM, Yang XJ: Topoisomerase II alpha expression in testicular germ cell tumors. Urology; 2007 May;69(5):955-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase II alpha expression in testicular germ cell tumors.
  • OBJECTIVES: Inhibitors of topoisomerase II alpha (TopoIIalpha), an enzyme with a crucial role in DNA maintenance, are included in the chemotherapy protocols for testicular germ cell tumors (GCTs).
  • Despite the success of current chemotherapy regimens, a significant number of patients experience relapse.
  • We analyzed TopoIIalpha expression in primary and metastatic testicular GCTs because this enzyme is a target for some antineoplastic agents.
  • The metastatic lesions from 11 of the patients with mixed GCTs included seven teratomas with mature components, five embryonal carcinomas, one yolk sac tumor, one choriocarcinoma, and one teratoma with immature components.
  • RESULTS: Most embryonal carcinoma (100%), yolk sac tumor (95%), seminoma (88%), and choriocarcinoma (62%) components of the GCTs were TopoIIalpha immunoreactive.
  • None of the teratoma specimens with mature elements expressed TopoIIalpha.
  • These findings imply that the variable chemoresponsiveness of testicular GCTs could have an underlying molecular basis.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / analysis. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / antagonists & inhibitors. DNA-Binding Proteins / metabolism. Neoplasms, Germ Cell and Embryonal / enzymology. Testicular Neoplasms / enzymology. Topoisomerase II Inhibitors
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / enzymology. Carcinoma, Embryonal / pathology. Choriocarcinoma / drug therapy. Choriocarcinoma / enzymology. Choriocarcinoma / pathology. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / enzymology. Endodermal Sinus Tumor / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Sampling Studies. Seminoma / drug therapy. Seminoma / enzymology. Seminoma / pathology. Sensitivity and Specificity. Teratoma / drug therapy. Teratoma / enzymology. Teratoma / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482942.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Topoisomerase II Inhibitors; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


7. Mandoky L, Geczi L, Bodrogi I, Toth J, Bak M: Expression of HER-2/neu in testicular tumors. Anticancer Res; 2003 Jul-Aug;23(4):3447-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HER-2/neu in testicular tumors.
  • BACKGROUND: Although the overexpression of the Epidermal Growth Factor Receptor 2 (EGFR-2, HER-2/neu, c-erbB-2) in malignancies might predict chemoresistance and poor prognosis, its clinical relevance has not been widely studied and determined in testicular tumors.
  • PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu receptor status of 28 primary testicular tumors (7 pure teratomas, 21 mixed germ cell tumors containing teratomatous components) using a standardized immunohistochemical method (HercepTest Kit).
  • Three of the 5 choriocarcinoma components of mixed tumors overexpressed HER-2/neu.
  • In one case (teratoma + choriocarcinoma) both components showed HER-2/neu overexpression.
  • Among the HER-2/neu-positive cases, 3 patients are in complete remission, 3 patients are in partial remission and one patient died after primary chemotherapy.
  • Further molecular investigations and clinicopathological studies are necessary to determine the correlation between HER-2/neu overexpression and clinical resistance of testicular tumors.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / metabolism. Receptor, ErbB-2 / biosynthesis. Testicular Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Choriocarcinoma / drug therapy. Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Humans. Immunohistochemistry. Male. Neoplasm Staging. Seminoma / drug therapy. Seminoma / metabolism. Seminoma / pathology. Teratoma / drug therapy. Teratoma / metabolism. Teratoma / pathology. Treatment Outcome


8. Nakano A, Yoshida M, Harada T, Araki A, Pineda L, Iijima M, Sezer C, Zhou L, Maruyama R: Intratubular germ cell neoplasia of unclassified type occupying the whole testis accompanied by a small mature teratoma and metastatic choriocarcinoma and Sertoli cell-only tubules in the other testis. Pathol Int; 2003 Oct;53(10):726-32
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratubular germ cell neoplasia of unclassified type occupying the whole testis accompanied by a small mature teratoma and metastatic choriocarcinoma and Sertoli cell-only tubules in the other testis.
  • A 19-year-old man with mild mental retardation was diagnosed as having metastatic choriocarcinoma and a testicular tumor.
  • Histopathological examination of the resected testis revealed the presence of a small lesion of mature teratoma but no trace of choriocarcinoma.
  • The remaining seminiferous tubules were atrophic and lined by large atypical germ cells, which were diagnosed as intratubular germ cell neoplasia of the unclassified type (IGCNU).
  • A small area with prominent tubules was also observed.
  • Within this lesion, the tubules were dilated and contained several layers of cells with central necrosis.
  • Immunohistological comparison of staining for several biological markers (Ki-67, c-kit and placental alkaline phosphatase) between cells in the atrophic tubules and those in the dilated tubules indicated a progression of the latter cells to cells with a more proliferative ability.
  • In the opposite testis, examined at autopsy after death due to metastatic choriocarcinoma, all seminiferous tubules were lined by Sertoli cells only.
  • It was therefore assumed that the germ cell tumor of the combined histological type had primarily arisen in the background of IGCNU, and that choriocarcinoma had spontaneously regressed.
  • The early onset of these testicular neoplastic lesions strongly indicates their occurrence under the genetic background of gonadal dysplasia, the Sertoli cell-only syndrome.
  • [MeSH-major] Choriocarcinoma, Non-gestational / secondary. Germinoma / pathology. Neoplasms, Multiple Primary / pathology. Seminiferous Tubules / pathology. Sertoli Cells / pathology. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Drug Therapy. Fatal Outcome. Humans. Immunohistochemistry. Male. Organ Size

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14516326.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Stang A, Rusner C, Eisinger B, Stegmaier C, Kaatsch P: Subtype-specific incidence of testicular cancer in Germany: a pooled analysis of nine population-based cancer registries. Int J Androl; 2009 Aug;32(4):306-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtype-specific incidence of testicular cancer in Germany: a pooled analysis of nine population-based cancer registries.
  • Comparisons of incidence estimates of testicular cancer subtypes beyond seminoma and non-seminoma are virtually missing in the epidemiologic literature.
  • We analysed incidence data from population-based German cancer registries to provide subtype-specific incidences of testicular cancer.
  • We pooled data from nine cancer registries from 1998 to 2003.
  • We estimated incidence and mortality time trends of West and East Germany.
  • In 1998-2003, the seminoma incidence rate was 5.1 per 100,000; among non-seminomas, the rates were the highest for malignant teratoma (1.6 per 100,000), followed by embryonal carcinoma (1.2 per 100,000).
  • Testicular lymphomas were rare (0.1 per 100,000).
  • The incidence of testicular cancer among children aged 0-14 years was nearly constant from 1987 through 2004.
  • In East and West Germany, rates of embryonal carcinoma in the early periods were considerably lower than the rates of malignant teratoma.
  • In the most recent periods, rates of embryonal carcinoma became quite similar to the rates of malignant teratoma.
  • The later start of the mortality decline in East Germany may be because of a later introduction of platinum-based chemotherapy compared to West Germany.
  • [MeSH-major] Testicular Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Embryonal / epidemiology. Child. Child, Preschool. Choriocarcinoma / epidemiology. Germany / epidemiology. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Population Surveillance. Registries. Seminoma / epidemiology. Teratoma / epidemiology. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179558.001).
  • [ISSN] 1365-2605
  • [Journal-full-title] International journal of andrology
  • [ISO-abbreviation] Int. J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. van de Geijn GJ, Hersmus R, Looijenga LH: Recent developments in testicular germ cell tumor research. Birth Defects Res C Embryo Today; 2009 Mar;87(1):96-113
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in testicular germ cell tumor research.
  • Testicular germ cell tumors of adolescents and adults (TGCTs; the so-called type II variant) are the most frequent malignancies found in Caucasian males between 20 and 40 years of age.
  • TGCTs are divided into seminomas and nonseminomas, the latter consisting of the subgroups embryonal carcinoma, yolk-sac tumor, teratoma, and choriocarcinoma.
  • Somatic differentiation is seen in the teratomas (all lineages), whereas yolk-sac tumors and choriocarcinoma represent extra-embryonal differentiation.
  • Seminomas are highly sensitive to irradiation and (DNA damaging) chemotherapy, whereas most nonseminomatous elements are less susceptible to radiation, although still sensitive to chemotherapy, with the exception of teratoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms, Germ Cell and Embryonal / metabolism. Seminoma / metabolism. Testicular Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306344.001).
  • [ISSN] 1542-9768
  • [Journal-full-title] Birth defects research. Part C, Embryo today : reviews
  • [ISO-abbreviation] Birth Defects Res. C Embryo Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  • [Number-of-references] 235
  •  go-up   go-down


11. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WHO classification of testicular tumors].
  • Twenty years after the first edition (1977), the WHO has presented the updated version of the "Histological typing of testis tumours".
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • Seminoma with syncytiotrophoblastic cells is a variant which should not be confused with choriocarcinoma.
  • Unfortunately, however, the old term "teratoma with malignant transformation" was changed to "teratoma with malignant areas" in the 1998 classification.
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.
  • [MeSH-major] Testicular Neoplasms / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


12. Brandes AA, Pasetto LM, Monfardini S: The treatment of cranial germ cell tumours. Cancer Treat Rev; 2000 Aug;26(4):233-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of cranial germ cell tumours.
  • Germ cell tumours of the central nervous system (CNS) include many subtypes whose response to treatment varies, even though the symptoms and radiological appearances are similar.
  • Patients with choriocarcinoma, embryonal carcinoma, or yolk sac tumour have the lowest survival rates; patients with germinoma or mature teratoma have longer survival rates.
  • Beside the delayed injury induced by radiotherapy, the late injury induced by chemotherapy is becoming increasingly evident.
  • Cisplatin is considered an indispensable drug, but it may cause renal damage, ototoxicity, peripheral neuropathy and sterility, while etoposide is associated with an excess frequency of second neoplasms.
  • Taking into account all of the published literature, the following therapeutic options are suggested: in pure germinoma tumours (GT) radiotherapy alone will usually ensure adequate control of the disease, and the long-term sequelae may be limited by reducing the dose delivered, as was proposed for germ cell testicular tumours, to 30 Gy to limited fields plus 25-30 Gy to the spinal axis if there is disseminated disease.
  • In cases of recurrence, which should be uncommon, patients may be rescued with both radiotherapy and chemotherapy.
  • In NGGC tumours, the prognosis is more unfavourable and there is often dissemination to the spine at diagnosis; however, the tumour's high chemosensitivity suggests neoadjuvant treatment chemotherapy with cisplatin and etoposide for three cycles followed by consolidation radiotherapy with 40 Gy to the limited fields plus 30 Gy to the spinal axis if disseminated.
  • In our opinion, a higher dose of radiotherapy in cases in which chemotherapy does not achieve a radiological complete remission is not advisable, because very often the residual radiological abnormality does not represent biologically active tumour but differentiated forms such as mature teratoma.
  • The challenge for 2000 is to both cure these patients, and avoid the late and permanent sequelae of radiation and/or chemotherapy that may subsequently impair quality of life.
  • [MeSH-major] Brain Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Combined Modality Therapy. Cranial Irradiation. Drug Therapy. Humans. Neurosurgical Procedures. Prognosis. Radiotherapy Dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 10913379.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] ENGLAND
  • [Number-of-references] 59
  •  go-up   go-down


13. You YN, Leibovitch BC, Que FG: Hepatic metastasectomy for testicular germ cell tumors: is it worth it? J Gastrointest Surg; 2009 Apr;13(4):595-601
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastasectomy for testicular germ cell tumors: is it worth it?
  • BACKGROUND: Chemotherapy is highly effective for metastatic germ cell tumor (GCT), but experience with resection of hepatic metastases from GCT is limited.
  • Pre-resection therapy, surgical pathology, and operative outcomes were reviewed.
  • Hepatic histology included: necrosis (33%), viable tumor (27%), mature teratoma (13%), and benign histology (27%).
  • Concomitant resection of extrahepatic disease (14 patients, 93%) found necrosis (53%), mature teratoma (27%), and viable tumor (13%).
  • CONCLUSION: Resection of post-chemotherapy hepatic disease is safe, even when combined with resection of extrahepatic residual disease.
  • [MeSH-minor] Adolescent. Adult. Choriocarcinoma / secondary. Choriocarcinoma / surgery. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Testicular Neoplasms / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2005 Aug;242(2):260-6 [16041217.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] N Engl J Med. 1997 Jul 24;337(4):242-53 [9227931.001]
  • [Cites] J Urol. 2004 Jan;171(1):168-71 [14665869.001]
  • [Cites] J Urol. 2004 May;171(5):1835-8 [15076288.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):125-35 [18156932.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5512-8 [17158536.001]
  • [Cites] Ann Thorac Surg. 1998 Nov;66(5):1709-14 [9875776.001]
  • [Cites] J Urol. 2006 Nov;176(5):1921-6 [17070212.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5603-8 [17998544.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):63-70 [12491506.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):578-87 [11505402.001]
  • [Cites] Curr Ther Endocrinol Metab. 1997;6:387-92 [9174777.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1033-7 [17261854.001]
  • [Cites] Ann Surg. 1990 Sep;212(3):290-3; discussion 293-4 [2168694.001]
  • [Cites] Urol Clin North Am. 2007 May;34(2):235-43; abstract x [17484928.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):207-18 [17963007.001]
  • [Cites] J Pathol. 2007 Sep;213(1):65-71 [17634958.001]
  • [Cites] Ann Oncol. 2006 Sep;17 Suppl 10:x31-5 [17018745.001]
  • [Cites] Urol Clin North Am. 2007 May;34(2):199-217; abstract ix [17484925.001]
  • [Cites] Surgery. 2007 Jan;141(1):9-18 [17188163.001]
  • [Cites] Semin Urol Oncol. 2002 Nov;20(4):262-71 [12489059.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):640-4 [10560848.001]
  • [Cites] Urol Clin North Am. 2007 May;34(2):187-97; abstract ix [17484924.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • (PMID = 19190967.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sarkar S, Kundu AK, Chakrabarti S: Lungs: victim of synchronous double malignancies. J Assoc Physicians India; 2007 Mar;55:235-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A lump in his left testis was detected during clinical examination.
  • Both FNAC and excisional biopsy of the testicular mass confirmed the diagnosis of immature teratoma with choriocarcinoma, a form of non-seminomatous germ cell tumour (NSGCT).
  • With chemotherapy all metastatic lesions of lung and SVC syndrome disappeared, and the tumour-marker levels decreased.
  • However, the opacity in RUZ progessed to involve right recurrent laryngeal nerve at thoracic inlet, metastasized to the brain, and the patient expired after 4th cycle of chemotherapy.
  • [MeSH-major] Choriocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Teratoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598338.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


15. Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, Gray E, McKeever P, Hale J, Bailey S, Oakhill A: The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol; 2000 Nov 15;18(22):3809-18
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
  • Stage I testicular and some ovarian GCTs were resected and monitored with alpha-fetoprotein (AFP) ("watch-and-wait" approach).
  • Chemotherapy toxicities were assessed using World Health Organization or Brock grading.
  • Eight were excluded because either there was no histologic diagnosis (n = 3) or chemotherapy was given off-study (n = 5).
  • The remaining 184 patients had germinoma (n = 20), malignant teratoma (n = 55), embryonal carcinoma (n = 1), yolk sac tumor (n = 107), or choriocarcinoma (n = 1).
  • The median follow-up after JEB treatment was 53 months (range, 0 to 109 months); the median number of courses was five (range, three to eight).
  • CONCLUSION: Conservative surgery, a watch-and-wait approach after complete excision, and JEB for those requiring chemotherapy produced high cure rates and few serious complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Ovarian Neoplasms / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Bleomycin / adverse effects. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Chorionic Gonadotropin / blood. Combined Modality Therapy. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Infant. Infant, Newborn. Male. Prognosis. Survival Analysis. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078494.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; JEB protocol
  •  go-up   go-down


16. Maroto P, García del Muro X, Aparicio J, Paz-Ares L, Arranz JA, Guma J, Terrassa J, Barnadas J, Dorta J, Germà-Lluch JR: Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol; 2005 Dec;16(12):1915-20
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other patients (358/589; 61%) were kept on close follow-up (chest X-ray; serum tumour markers: first year every 2 months, second year every 3 months, third year every 4 months; abdominal computed tomography scans at every other outpatient control).
  • In the chemotherapy group, two patients relapsed at 12 and 14.5 months and they are presently free of disease.
  • Five (1.4%) patients died of their cancer.
  • Factors associated with relapse were embryonal carcinoma and vascular invasion in patients who refused chemotherapy.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16126737.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


17. Allan RW, Algood CB, Shih IeM: Metastatic epithelioid trophoblastic tumor in a male patient with mixed germ-cell tumor of the testis. Am J Surg Pathol; 2009 Dec;33(12):1902-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic epithelioid trophoblastic tumor in a male patient with mixed germ-cell tumor of the testis.
  • This report describes a rare case of a concurrent epithelioid trophoblastic tumor (ETT) and a teratoma in a para-aortic lymph node from a 39-year-old male patient with the initial diagnosis of testicular malignant mixed germ-cell tumor.
  • The metastatic lesion was excised 2 years after orchiectomy and chemotherapy.
  • Microscopically, the metastatic lesion contained a teratoma component and dispersed small nests of cohesive chorionic-type intermediate trophoblastic cells, closely resembling gestational ETT in female patients.
  • Demonstration of ETT as one of the histologic manifestations of recurrent testicular germ-cell tumors should encourage pathologists to recognize this unique feature in assessing posttreatment mixed germ-cell neoplasm.
  • [MeSH-major] Carcinoma, Embryonal / secondary. Choriocarcinoma, Non-gestational / secondary. Epithelioid Cells / pathology. Teratoma / secondary. Testicular Neoplasms / pathology. Trophoblastic Neoplasms / secondary
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Orchiectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898219.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Shintaku I, Satoh M, Okajima E, Fujimoto H, Kamoto T, Ogawa O, Kawai K, Akaza H, Tsukamoto T, Naito S, Miki T, Arai Y: Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan. Jpn J Clin Oncol; 2008 Apr;38(4):281-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.
  • This increase is most likely attributed to more effective chemotherapy regimens and more extensive care in the experienced institutes.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / mortality. Testicular Neoplasms / diagnosis. Testicular Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Choriocarcinoma / diagnosis. Choriocarcinoma / epidemiology. Disease-Free Survival. Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / epidemiology. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Seminoma / diagnosis. Seminoma / epidemiology. Survival Rate. Teratoma / diagnosis. Teratoma / epidemiology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321891.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Roth LM, Talerman A: Recent advances in the pathology and classification of ovarian germ cell tumors. Int J Gynecol Pathol; 2006 Oct;25(4):305-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The introduction of cisplatin-based chemotherapy and the discovery of tumor markers, including alpha-fetoprotein and human chorionic gonadotropin, have dramatically changed the clinical outlook for most of these patients.
  • Where appropriate, comparisons are made with testicular germ cell tumors.
  • [MeSH-minor] Carcinoid Tumor / classification. Carcinoid Tumor / pathology. Carcinoma, Embryonal / classification. Carcinoma, Embryonal / pathology. Choriocarcinoma / classification. Choriocarcinoma / pathology. Dysgerminoma / classification. Dysgerminoma / pathology. Endodermal Sinus Tumor / classification. Endodermal Sinus Tumor / pathology. Female. Humans. Teratoma / classification. Teratoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990705.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 102
  •  go-up   go-down


20. Williams SB, Steele GS, Richie JP: Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer. J Urol; 2009 Dec;182(6):2716-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
  • PURPOSE: Initial management for clinical stage IS (persistently increased tumor markers) nonseminomatous germ cell tumor has evolved from primary retroperitoneal lymph node dissection to induction chemotherapy at most medical centers.
  • MATERIALS AND METHODS: We reviewed the charts of patients who underwent retroperitoneal lymph node dissection at Brigham and Women's Hospital, and Dana Farber Cancer Center from 1993 to 2008.
  • Histopathology revealed an embryonal carcinoma component in 24 orchiectomy specimens (100%) with associated teratoma in 15 (63%).
  • Positive lymph nodes were identified at retroperitoneal lymph node dissection in 9 patients (38%), including pure embryonal carcinoma in 6 (67%), combined embryonal carcinoma and teratoma in 1, embryonal carcinoma, choriocarcinoma and teratoma in 1, and only teratoma in 1.
  • Of the patients who underwent primary retroperitoneal lymph node dissection 5 (21%) also received chemotherapy postoperatively, which was due to persistently increased tumor markers in 3 (13%).
  • At surgery estimated blood loss was 175 cc, operative time was 3.1 hours and hospital stay was 3.9 days.
  • CONCLUSIONS: Patients with clinical stage IS are at significant risk for metastatic disease and can be successfully treated with primary retroperitoneal lymph node dissection, thereby sparing chemotherapy in most of them.
  • [MeSH-major] Lymph Node Excision / methods. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2009 Dec;182(6):2720 [19836765.001]
  • (PMID = 19836777.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement